A clinical trial in head and neck cancer explored ways to improve clinical outcomes for patients, and although the trial failed, researchers found insight into new ways to address treatment resistance. Treatment is limited, relying on aggressive surgery and insufficient therapeutics, which leaves patients with few options; researchers at the University of Michigan Rogel Cancer Center have been searching for ways to fundamentally change the approach to treating laryngeal cancer. Paul Swiecicki, M.D., clinical associate professor in medical oncology, says that Michigan Medicine was instrumental in changing this therapeutic course and discusses new ways to treat head and neck cancer.
